Alpha Teknova

TKNO

Börsenwert 380 Mio. $

Teknova and Pluristyx announce a Type II FDA Drug Master File for the PluriFreeze™ cryopreservation system, now available to developers for cross-reference

Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Teknova's Fill-Tek™ Dispensing System fills single-use bag orders across multiple sizes and quantities as a single lot, with no added turnaround time.

Alpha Teknova NASDAQ: TKNO Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve.

Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

The mean of analysts' price targets for Alpha Teknova (TKNO) points to a 35.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Alpha Teknova NASDAQ: TKNO reported second-quarter revenue growth of 18% from a year earlier, surpassing $12 million for its highest quarterly revenue in the company's 30-year history. The company raised its full-year revenue outlook, citing first-half performance and confidence in the second half of 2026.

Alpha Teknova, Inc. (TKNO) Q2 2026 Earnings Call Transcript

Second quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior year Company raises 2026 revenue guidance to $45-47 million Launched proprietary AI-powered Build-Tek™  custom order configurator, giving developers a faster path from preclinical to clinical manufacturing HOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2026.